Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.41 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2645265 | 0.95 | DPP4 (0.42) | DPP4GRM7ALDH1A1 | |
| SCHEMBL2645548 | 0.82 | ATM (0.32) | SMN1; SMN2ALDH1A1RAB9AATMMEN1 | |
| SCHEMBL2645433 | 0.77 | DPP4 (0.43) | DPP4ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL2645234 | 0.77 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL2644912 | 0.76 | L3MBTL1 (0.38) | SMN1; SMN2ALDH1A1ATMMEN1KMT2A | |
| SCHEMBL2645771 | 0.75 | ALDH1A1 (0.36) | ALDH1A1ATMKMT2ATSHR | |
| SCHEMBL2646658 | 0.74 | L3MBTL1 (0.46) | SMN1; SMN2ALDH1A1RAB9AATMMEN1 | |
| SCHEMBL2645015 | 0.74 | ATM (0.37) | SMN1; SMN2ALDH1A1ATMMEN1KMT2A | |
| SCHEMBL2645027 | 0.74 | DPP4 (0.47) | DPP4SMN1; SMN2ALDH1A1RAB9AATM | |
| SCHEMBL7837036 | 0.73 | L3MBTL1 (0.53) | SMN1; SMN2ALDH1A1ATMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1702919-B1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | MSD KK (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-7728025-B2 | 2-heteroaryl-substituted benzimidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1702919-A1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | GCK, GCKR, HK1 | DPP4 91/4885GRM7 2274/4885SMN1; SMN2 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.